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doi:10.1016/j.jtcvs.2007.12.036452 The Journal of Thoracic and CardObjective: Elevated B-type natriuretic peptide is associated with increased morbidity
and mortality in ambulatory patients with congestive heart failure or acute coronary
syndromes. Its utility in predicting adverse cardiac surgical outcomes is less certain.
We hypothesized that preoperative plasma B-type natriuretic peptide would indepen-
dently predict in-hospital postoperative ventricular dysfunction, hospital stay, and up
to 5-year mortality after primary coronary artery bypass grafting.
Methods: This is a prospective, longitudinal study of 1023 patients at two institutions
undergoing primary coronary artery bypass grafting with cardiopulmonary bypass.
Ventricular dysfunction was defined as requirement for at least two inotropes or
new intra-aortic balloon pump or ventricular assist device support after coronary
artery bypass grafting. Multivariable analyses assessed independent roles of preoper-
ative B-type natriuretic peptide in predicting postoperative ventricular dysfunction,
hospital stay, and 5-year all-cause mortality.
Results: Preoperative plasma B-type natriuretic peptide concentration predicted
ventricular dysfunction, hospital stay, and mortality in univariate and multivariable
analyses. Logistic regression demonstrated preoperative B-type natriuretic peptide
to independently predict ventricular dysfunction (odds ratio 1.92, 95% confidence
interval 1.12–3.29, P 5 .018), after adjustment for preoperative left ventricular ejec-
tion fraction, congestive heart failure severity, and other clinical predictors. Multivari-
able Cox proportional hazards models showed preoperative B-type natriuretic peptide
to independently predict hospital stay (hazard ratio 1.42, 95% confidence interval
1.18–1.72, P 5 .0002) and mortality (hazard ratio 1.89, 95% confidence interval
1.08–3.33, P 5 .026).
Conclusion: Preoperative plasma B-type natriuretic peptide independently predicted
in-hospital ventricular dysfunction, hospital stay, and up to 5-year all-cause mortality
after primary coronary artery bypass grafting.
B
-type natriuretic peptide (BNP) is secreted by cardiac ventricular myocytes in
response to increased ventricular wall tension and promotes compensatory
diuresis, natriuresis, and inhibition of the renin-angiotensin-aldosterone
axis.1 Elevated plasma BNP independently predicts intermediate to long-term
morbidity and mortality in ambulatory patients with congestive heart failure
(CHF)2-5 or acute coronary syndromes.6-9 For noncardiac surgical patients, elevated
preoperative BNP independently predicts a composite of in-hospital adverse cardiac
events, including cardiac death.10 Studies of the utility of preoperative plasma BNP
for identifying risk in cardiac surgical patients have been inconsistent, probably
because of limitations of small sample sizes or inclusion of diverse cardiac surgical
procedures.11-15 We hypothesized that elevated preoperative BNP would indepen-
dently predict the occurrence of in-hospital postoperative ventricular dysfunction
and longer term all-cause mortality in patients undergoing primary coronary arteryiovascular Surgery c August 2008
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CDAbbreviations and Acronyms
BNP 5 B-type natriuretic peptide
CABG 5 coronary artery bypass grafting
CHF 5 congestive heart failure
CI 5 confidence interval
CPB 5 cardiopulmonary bypass
cTnI 5 cardiac troponin I
IABP 5 intra-aortic balloon pump
LVEF 5 left ventricular ejection fraction
POD 5 postoperative day
VAD 5 ventricular assist device
bypass grafting (CABG) with cardiopulmonary bypass
(CPB), even after adjustment for other established predictors
of perioperative risk. We further hypothesized that incorpo-
rating preoperative plasma BNP data into established cardiac
surgical mortality risk prediction models would significantly
improve their ability to predict all-cause mortality up to 5
years after CABG.
Methods
Study Participants
Patients aged 21 to 89 years undergoing primary CABG alone with
CPB at Brigham and Women’s Hospital, Boston, Mass, and Texas
Heart Institute, St Luke’s Episcopal Hospital, Houston, Tex, be-
tween August 2001 and June 2005 were enrolled consecutively
into a prospective parent study (CABG Genomics Research Study,
http://clinicaltrials.gov/show/NCT00281164)16 with the overall aim
of identifying relationships among genotypic variation, biomarkers,
and adverse perioperative outcomes. Institutional review board
approval was obtained, and written informed consent was obtained
from each patient before enrollment. Exclusion criteria included
a preoperative hematocrit less than 25% or administration of leuko-
cyte-rich blood products within 30 days before surgery. Patients
undergoing emergency surgery; patients requiring preoperative ino-
tropes, a preoperative intra-aortic balloon pump (IABP), or a ventric-
ular assist device (VAD); and patients missing preoperative BNP
data were prospectively excluded from analysis. Patients with
severe renal dysfunction (preoperative hemodialysis or serum creat-
inine.3 mg/dL) were also excluded from analysis because of con-
cern that perioperative dialysis would variably affect perioperative
plasma BNP concentrations.17,18
Data and Blood Collection
Data were collected for each enrolled patient during primary
hospitalization with a study-specific case report form that included
patient demographic information, perioperative risk factors, medica-
tions, perioperative medical and surgical parameters, and post-
operative outcomes. To verify accuracy of records, computerized
range and logic checking were automatically performed on all
records, as was a manual audit of a proportion of records. Postopera-
tive patient survival was assessed annually by mail and telephone
questionnaires and by examination of the Social Security mortality
index.The Journal of ThoPlasma and serum samples obtained preoperatively and on post-
operative days (PODs) 1 through 5 were stored in vapor-phase liq-
uid nitrogen at 270C until analysis. Preoperative (day of surgery)
plasma BNP and cardiac troponin I (cTnI) and postoperative plasma
BNP concentrations (PODs 1, 3, and 5) were measured at the Brig-
ham and Women’s Hospital Clinical Laboratory with ADVIA Cen-
taur BNP and cTnI immunoassays (Siemens Medical Solutions
Diagnostics, Tarrytown, NY). Timing choices for postoperative
BNP measures were based on the occurrence of peak postoperative
plasma BNP concentrations obtained from a pilot study of 116
CABG Genomics Research Study patients (data not shown).
Definitions
Postoperative ventricular dysfunction was defined as new require-
ment for at least 2 inotropes or the need for IABP or VAD insertion
either intraoperatively after separation from CPB or postoperatively
in the intensive care unit. Intraoperative and postoperative inotropic
support was defined as continuous infusion of amrinone, dobut-
amine, dopamine (.5 mg/[kg $ min]), epinephrine, isoproterenol,
milrinone, norepinephrine, or vasopressin. A dyspnea score was
derived from the New York Heart Association classification, with
a score of 1 indicating no dyspnea, a score of 2 indicating mild im-
pairment of daily functioning, a score of 3 indicating substantial
functional impairment when not at rest, and a score of 4 indicating
functional impairment at rest.19 Urgent CABG was defined as sur-
gery occurring within the same hospitalization as the diagnosis of
an acute coronary event or coronary artery disease. Stenosis greater
than 50% of the left anterior descending, left circumflex, or right
coronary artery or of their major branches were quantified according
to cardiac catheterization data and scored as regions of coronary ar-
terial disease (1, 2, or 3 regions total). Stenosis greater than 50% of
the left main coronary artery was counted as 2 regions of significant
disease. Hospital stay included date of surgery and date of discharge
as complete days of stay, with a 30-day postoperative follow-up
period for this outcome. Extended hospital stay was defined as
longer than 12 days (90th percentile) after surgery. Mortality was
defined as death from any cause during the 5-year follow-up period
after surgery.
Statistical Analysis
Statistical analyses were performed with SAS (version 9.1; SAS
Institute, Inc, Cary, NC). On the basis of data from a previously con-
ducted pilot study (n5 116), required sample size was estimated for
greater than 99% power and a type I error of .05. This stringent
power requirement was chosen to allow adequate sample size for
assessment of preoperative BNP concentration as an independent
predictor of postoperative ventricular dysfunction after adjustment
for multiple covariates. Accordingly, at least 100 patients with ven-
tricular dysfunction were needed to detect significant differences in
baseline BNP concentrations.
Preoperative plasma BNP data were log10 transformed to a nor-
mal distribution before analysis. To examine the effects of preoper-
ative BNP concentrations and other perioperative covariates on
ventricular dysfunction, hospital stay, and 5-year postoperative mor-
tality, c2 or Fisher exact tests were used for categoric covariates and
Wilcoxon–Mann–Whitney rank sum tests were used for continuous
covariates. Mantel–Haenszel c2 tests were used for ordinal vari-
ables. Paired comparisons were made when appropriate. Log-rankracic and Cardiovascular Surgery c Volume 136, Number 2 453
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ative covariates and postoperative survival. To assess the relation-
ship between preoperative BNP and other perioperative covariates
with regard to in-hospital ventricular dysfunction, hospital stay,
and 5-year mortality, covariates with a 2-tailed nominal P value
less than .15 in univariate analyses and additional demographic vari-
ables were entered into a stepwise multivariable logistic regression
for analysis of ventricular dysfunction and into Cox proportional
hazards models for analysis of hospital stay and 5-year postopera-
tive mortality. In the hospital stay analysis, patients who died within
30 days of surgery were counted as having a hospital stay of 30 days.
Because plasma BNP concentration has been shown to increase with
age,20 female sex,20 renal dysfunction,18 and reduced left ventricular
ejection fraction (LVEF) and to decrease with obesity,21 these cova-
riates were adjusted for in all multivariable analyses. Receiver oper-
ating characteristic curves were used to assess the relationship of
preoperative BNP concentrations to postoperative ventricular dys-
function and mortality. Kaplan–Meier survival curves were con-
structed as appropriate, with Wilcoxon rank tests used to assess
significant differences between stratified curves.
To assess the value of adding preoperative BNP concentration to
established risk stratification models for predicting mortality after
CABG, risk scores for each patient were calculated with the Cleve-
land Clinic,22 EuroSCORE additive23 and logistic,24 modified Par-
sonnet,25 and New York State (www.health.state.ny.us/nysdoh/
consumer/heart/1996-98cabg.pdf) models. Of 19 well-known car-
diac surgical risk scoring systems, these five risk scores have been
shown to be best in predicting 1-year mortality after CABG.26 We
used three statistical approaches (Nagelkerke generalized r2,27 the
likelihood ratio test, and Akaike information criterion28) to assess
the benefit of adding preoperative BNP data to the five mortality
risk scores to predict 5-year postoperative mortality. We also used
these three statistical approaches to assess the abilities of the multi-
variable models developed in this study to predict postoperative
ventricular dysfunction, hospital stay, and mortality with and with-
out inclusion of preoperative BNP. F tests were used to compare
generalized r2, and the likelihood ratio test statistic had an asymp-
totic c2 distribution.
Results
Of 1162 patients enrolled in the parent study, 139 were
excluded from analysis for one or more of the following pro-
spectively determined exclusion criteria: emergency surgery
(n5 4); previous CABG (n5 1); valve (n5 2); or other car-
diac (n 5 15) surgery; off-pump surgery (n 5 39); preoper-
ative hemodialysis (n 5 1) or preoperative serum creatinine
level greater than 3 mg/dL (n 5 4); preoperative inotropes
(n 5 4); preoperative IABP (n 5 27) or VAD use (n 5 1);
concurrent cardiac valve surgery (n 5 50); and missing
preoperative BNP concentration (n 5 12).
Patient Characteristics
Perioperative patient characteristics for the 1023 patients in-
cluded in the study analysis are shown in Table 1 and are
stratified by occurrence of postoperative ventricular dysfunc-
tion. Table 2 shows the type of ventricular support required
by the patients with ventricular dysfunction. Patients with454 The Journal of Thoracic and Cardiovascular Surgery c Aupostoperative ventricular dysfunction were significantly
more likely to have higher preoperative BNP concentrations,
as well as preoperative renal insufficiency; recent myocardial
infarction according to patient history; preoperative cTnI
level greater than 0.1 mg/L; reduced LVEF; higher dyspnea
score; higher pack-year smoking history; preoperative angio-
tensin-converting enzyme inhibitor, diuretic, and digoxin
use; and longer CPB and aortic crossclamp times (Table 1).
Relationship of Ventricular Dysfunction to Hospital
Stay and Postoperative Survival
Patients with postoperative ventricular dysfunction had a sig-
nificantly higher incidence of extended hospital stay (odds
ratio 6.16, 95% confidence interval [CI] 3.88–9.77, P ,
.0001) than patients without postoperative ventricular
dysfunction. During the 5-year postoperative follow-up
period, 72 patients (7.0%) died, with mean time between
surgery and death being 1.8 6 1.4 years (range 0–5 years).
Because only 10 patients died within 30 days after surgery,
we did not assess predictors of short-term postoperative mor-
tality. Mean follow-up for the 951 living patients was 3.6 6
1.0 years (range 1.7–5 years), with 31.0% and 11.5% of
patients having reached the 4- and 5-year follow-up points,
respectively. Patients with postoperative ventricular dysfunc-
tion had significantly lower survival during the 5-year
follow-up period (odds ratio 3.58, 95% CI 2.07–6.21, P ,
.0001) than did patients without postoperative ventricular
dysfunction (Figure 1).
Relationship of Preoperative BNP to Postoperative
Ventricular Dysfunction and Hospital Stay
Patients with ventricular dysfunction had significantly higher
BNP concentrations at all perioperative time points relative to
patients without ventricular dysfunction (Figure 2). Patients
without postoperative ventricular dysfunction had BNP
concentrations that peaked on POD 3 and then declined sig-
nificantly, whereas patients with postoperative ventricular
dysfunction had BNP concentrations that remained elevated
throughout the observed postoperative period, without signif-
icant differences between PODs 3 and 5.
The value of preoperative BNP concentration for predict-
ing postoperative ventricular dysfunction was evaluated after
adjustment for the demographic characteristics of age, sex,
and ethnicity; body mass index; institution; and other likely
clinical predictors of postoperative ventricular dysfunction,
including preoperative angiotensin-converting enzyme in-
hibitor use, heart failure score, renal insufficiency, and the
other predictors listed in Table 3. Preoperative BNP con-
centration independently predicted postoperative ventricular
dysfunction (odds ratio 1.92, 95% CI 1.12–3.29, P 5 .018).
Addition of preoperative BNP to the multivariable model for
predicting postoperative ventricular dysfunction (Table 3)
significantly improved the model’s predictive ability, as indi-
cated by significant changes in the generalized r2 (P5 .0004)gust 2008
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DTABLE 1. Patient characteristics stratified by ventricular dysfunction after primary coronary artery bypass grafting
No dysfunction
(n 5 904)
Dysfunction
(n 5 119) P value
Preoperative characteristics
Age (y, mean 6 SD) 63.7 6 10.2 63.8 6 10.6 .75
Female 169 (18.7%) 20 (16.8%) .62
White 771 (85.3%) 102 (85.7%) .90
Institution .38
Brigham and Women's Hospital 665 (73.6%) 92 (77.3%)
Texas Heart Institute 239 (26.4%) 27 (22.7%)
Diabetes mellitus (n 5 1022) 243 (26.9%) 41 (34.5%) .08
Hypertension (n 5 1020) 681 (75.6%) 92 (77.3%) .68
Hypercholesterolemia (n 5 1019) 682 (75.6%) 93 (79.5%) .36
Obesity (body mass index .30 kg/m2) 347 (38.4%) 49 (41.2%) .56
Current smoker (n 5 1017) 114 (12.7%) 10 (8.5%) .19
Smoking (.30 pack-year history, n 5 972) 231 (26.7%) 41 (38.7%) .009
Renal insufficiency (creatinine 1.6–3.0 mg/dL, n 5 1022) 44 (4.9%) 13 (10.9%) .007
Myocardial infarction #2 wk preoperatively (n 5 1022) 137 (15.2%) 40 (33.6%) ,.0001
Left ventricular ejection fraction (%, mean 6 SD, n 5 973) 53.7 6 11.5 43.1 6 15.8 ,.0001
Dyspnea score (per New York Heart Association classification, n 5 928) .02
None or mild 435 (52.9%) 48 (45.3%)
Moderate 301 (36.6%) 38 (35.9%)
Severe 86 (10.5%) 20 (18.9%)
Coronary artery regions with .50% stenosis (n 5 1008) .14
0–1 50 (5.6%) 3 (2.5%)
2 141 (15.9%) 17 (14.3%)
3 698 (78.6%) 99 (83.2%)
Mitral insufficiency, moderate or severe (n 5 975) 16 (1.9) 5 (4.4) .09
Past arrhythmia (n 5 1022) 79 (8.8%) 12 (10.1%) .63
Preoperative B-type natriuretic peptide (pg/mL, median, 10th–90th percentile) 56.6 (11.2–250.7) 132.1 (19.0–696.9) ,.0001
Preoperative cardiac troponin I .0.1 mg/L (n 5 982) 238 (27.4%) 55 (48.7%) ,.0001
Preoperative medications
Angiotensin-converting enzyme inhibitor (n 5 1022) 397 (44.0%) 71 (59.7%) .001
Diuretic (n 5 1022) 165 (18.3%) 40 (33.6%) ,.0001
Statin 686 (75.9%) 90 (75.6%) .95
Digoxin (n 5 1022) 23 (2.6%) 8 (6.7%) .01
b-Blocker 679 (75.1%) 96 (80.7%) .18
Aspirin 674 (74.6%) 91 (76.5%) .65
Nonaspirin platelet inhibitor (n 5 1022) 176 (19.5%) 25 (21.0%) .70
Intravenous heparin (n 5 1022) 205 (22.7%) 37 (31.1%) .04
Intravenous nitrate (n 5 1020) 104 (11.5%) 16 (13.5%) .54
Intraoperative characteristics
Urgent surgery (n 5 1021) 470 (52.1%) 68 (57.1%) .30
Cardiopulmonary bypass time (min, mean 6 SD) 93.3 6 37.0 107.9 6 33.3 ,.0001
Aortic crossclamp time (min, mean 6 SD, n 5 1007) 68.4 6 32.0 76.1 6 29.5 .004
No. of coronary grafts (n 5 1022) .14
1–2 146 (16.2%) 11 (9.2%)
3 398 (44.1%) 57 (47.9%)
$4 359 (39.8%) 51 (42.9%)
Data are number and percentage of patients except as indicated.A
Cand the likelihood ratio statistic (P 5 .016). The 75th (141
pg/mL) and the 90th (292 pg/mL) percentiles of preoperative
BNP concentrations had high specificity but lower sensitivity
for predicting postoperative ventricular dysfunction, as
shown in Figure 3.The Journal of ThoBecause ventricular dysfunction is significantly associ-
ated with both extended hospital stay and 5-year postopera-
tive mortality, we also assessed the value of preoperative
BNP concentration for predicting postoperative hospital
stay. Elevated preoperative BNP significantly increasedracic and Cardiovascular Surgery c Volume 136, Number 2 455
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95% CI 1.18–1.72, P 5 .0002) after adjustment for demo-
graphic characteristics, institution, CPB time, and preopera-
tive variables including medications, LVEF, cTnI, renal
insufficiency, heart failure score, pack-year smoking history,
and number of diseased coronaries. Addition of preoperative
BNP to the multivariable model for predicting postoperative
hospital stay significantly improved the model’s predictive
ability, as indicated by significant changes in the generalized
r2 (P 5 .0002) and the likelihood ratio statistic (P 5 .0002).
TABLE 2. Type of ventricular support required by 119
patients with ventricular dysfunction after primary
coronary artery bypass grafting
Patients with dysfunction
Type of ventricular support Intraoperative Postoperative
2 Inotropes 57 (47.9%) 46 (38.7%)
$3 Inotropes 9 (7.6%) 24 (20.2%)
Intra-aortic balloon pump
insertion time
19 (16.0%) 12 (10.1%)
Ventricular assist device
insertion time
0 (0%) 1 (0.8%)
Inotrope
Amrinone 2 (1.7%) 2 (1.7%)
Milrinone 14 (11.8%) 19 (16.0%)
Dobutamine 6 (5.0%) 6 (5.0%)
Isoproterenol 1 (0.8%) 2 (1.7%)
Dopamine (.5 mg/[kg $ min]) 19 (16.0%) 16 (13.4%)
Epinephrine 87 (73.1%) 75 (63.0%)
Norepinephrine 39 (32.8%) 42 (35.3%)
Vasopressin 9 (7.6%) 40 (33.6%)
Data are number and percentage of patients with ventricular dysfunction.
Figure 1. Kaplan–Meier survival curves for all patients to 5 years
after primary coronary artery bypass grafting according to pres-
ence or absence of postoperative ventricular dysfunction (VnD).
Vertical bars indicate 95% confidence intervals for survival esti-
mates for each year of postoperative follow-up.456 The Journal of Thoracic and Cardiovascular Surgery c AuRelationship of Preoperative BNP to Postoperative
Survival
The preoperative BNP concentrations of patients who died
during the 5-year postoperative follow-up period (median
111 pg/mL, 10th–90th percentile 19–473 pg/mL)were signif-
icantly higher (P5 .0003) than the preoperative BNP concen-
trations of those who survived (median 58 pg/mL, 10th–90th
percentile 12–275 pg/mL). In a proportional hazards regres-
sion model with adjustment for sex, ethnicity, institution,
and the covariates shown in Table 4, preoperative BNP con-
centration independently predicted postoperative mortality
(hazard ratio 1.89, 95% CI 1.08–3.33, P 5 .026). Addition
of preoperative BNP significantly improved the model’s abil-
ity to predict postoperative mortality, as indicated by signifi-
cant changes in the generalized r2 (P 5 .003) and the
likelihood ratio statistics (P5 .024). On the basis of receiver
operating characteristic analysis, the 75th and 90th percentiles
of preoperative BNP concentrations had high specificity but
lower sensitivity for predicting 5-year postoperative mortal-
ity. The receiver operating characteristic curve and related
specificities, sensitivities, positive and negative predictive
values, and accuracies for the 75th and 90th percentile BNP
cutoffs are shown in Figure 4. Survival was significantly
Figure 2. Perioperative plasma B-type natriuretic peptide (BNP)
concentrations for all patients stratified according to presence
or absence of postoperative in-hospital ventricular dysfunction
(VnD),with 10th, 25th, 50th, 75th, and 90th percentile values shown
for each subgroup at each time point. Asterisk signifies P < .0001
for ventricular dysfunction versus no ventricular dysfunction;
dagger signifies P < .0001 versus preoperative baseline; double
dagger signifies P < .0001 versus previous postoperative day;
section mark signifies P 5 .02 versus previous postoperative day.gust 2008
Fox et al Surgery for Acquired Cardiovascular DiseaseTABLE 3. Multivariable analysis of ventricular dysfunction after primary coronary artery bypass grafting
With preoperative BNP in model
(n 5 843*; AIC 5 553.05)
Without preoperative BNP in model
(n 5 843*; AIC 5 556.88)
Predictor
Odds
Ratio
95% Confidence
Interval P value
Odds
Ratio
95% Confidence
Interval P value
Preoperative BNP (log10) 1.92 1.12–3.29 .018 — — —
Preoperative left ventricular ejection fraction (%) 0.97 0.95–0.99 .0006 0.96 0.94–0.98 ,.0001
Cardiopulmonary bypass $120 min 2.28 1.40–3.72 .001 2.35 1.45–3.81 .0006
Preoperative cardiac troponin I .0.1 mg/L 1.83 1.13–2.96 .013 2.11 1.33–3.35 .002
Preoperative diuretic 1.7 1.02–2.85 .031 1.81 1.08–3.04 .025
BNP, B-type natriuretic peptide; AIC, Akaike information criterion. *One or more of the model's predictor variables were missing for 180 subjects who were
therefore not included in this analysis.A
CDpredicted by both the 75th and 90th percentile preoperative
BNP cutoffs (P5 .0003 and 0.0016, respectively; Figure 5).
Preoperative BNP and Established Risk Models
for Mortality After Cardiac Surgery
We used three different statistical assessments of model per-
formance to determine whether preoperative BNP data im-
proved the ability of five established cardiac surgical risk
models to predict 5-year postoperative mortality in our pa-
tients undergoing primary CABG (Table 5). Mortality pre-
dictions from all five risk models improved significantly
Figure 3. Receiver operating characteristic curve describing pre-
operative plasma B-type natriuretic peptide (BNP) concentrations
in relation to in-hospital ventricular dysfunction after primary
coronary artery bypass grafting.The Journal of Thorwith the addition of preoperative BNP data, as determined
by at least one statistical assessment of model performance.
The improvement in the logistic EuroSCORE model, how-
ever, was seen only with marginal improvement in one
assessment of model performance (generalized r2).
Discussion
Significant morbidity is reported in 18% to 43% of patients
undergoing CABG29 and has important implications for
health care costs, quality of life, and survival. Currently used
cardiac surgical risk stratification models demonstrate only
a modest ability to predict postoperative mortality.22-26,29
Consequently, there is a need for models that accurately pre-
dict specific major morbidity as well as mortality after cardiac
surgery,22,25,29 because this may enable targeted implementa-
tion of therapeutic interventions. Although risk stratification
models have traditionally incorporated clinical patient charac-
teristics, there is increasing use of biomarkers in addition
to clinical parameters, particularly for ambulatory popula-
tions.6-9 We investigated the benefit of adding preoperative
BNP concentration to clinical patient characteristics to predict
morbidity and mortality after primary CABG.
We found that preoperative BNP concentration indepen-
dently predicted increased postoperative in-hospital ventricu-
lar dysfunction, hospital stay, and 5-year mortality after
primary CABG, after adjustment for clinical predictors.
This suggests that preoperative BNP is a useful addition to
classically accepted clinical risk factors, such as preoperative
myocardial infarction or low LVEF, for identifying patients
at high risk for perioperative morbidity and mortality. Similar
to findings in acute coronary syndrome populations,6-9 we
found that preoperative BNP provided prognostic informa-
tion for patients undergoing CABG that is additional to that
provided by preoperative cTnI. Furthermore, to our knowl-
edge, this study is the first to identify a predictive benefit of
adding preoperative BNP data to multiple established cardiac
surgical risk stratification models.
Most previous studies that have investigated preoperative
BNP as a predictor of adverse events after cardiac surgeryacic and Cardiovascular Surgery c Volume 136, Number 2 457
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bypass grafting
With preoperative BNP in model
(n 5 924*; AIC 5 761.97)
Without preoperative BNP in model
(n 5 924*; AIC 5 765.04)
Predictor
Hazard
Ratio
95% Confidence
Interval P value
Hazard
Ratio
95% Confidence
Interval P value
Preoperative BNP (log10) 1.89 1.08–3.33 .026 — — —
Age (10-y increment) 1.71 1.30–2.26 .0001 1.84 1.40–2.42 ,.0001
Smoking (.30 pack-y) 2.38 1.39–4.07 .002 2.50 1.46–4.27 .0008
Urgent procedure 1.85 1.05–3.25 .033 1.94 1.11–3.41 .021
Body mass index .30 kg/m2 2.13 1.26–3.62 .005 1.93 1.15–3.25 .013
Preoperative angiotensin-converting enzyme inhibitor 0.58 0.34–0.99 .044 0.57 0.34–0.98 .042
Left ventricular ejection fraction (%) 0.98 0.96–1.00 .060 0.97 0.95–0.99 .005
BNP, B-type natriuretic peptide; AIC, Akaike information criterion. *One or more of the model's predictor variables were missing for 99 subjects who were
therefore not included in this analysis.have been underpowered. Univariate analyses have shown
that preoperative BNP predicts such adverse outcomes as
postoperative LVEF,11,12 inotrope requirements,11 mechani-
cal ventricular support,15 postoperative cTnI concentration,13
hospital stay,15 and mortality.13,15 A prospective study of pa-
tients undergoing CABG or valve surgery found that preoper-
ative and POD 1 BNP concentrations predicted postoperative
CHF and 1-year survival in univariate analysis; however, that
study did not assess preoperative BNP in multivariable
Figure 4. Receiver operating characteristic curve describing pre-
operative plasma B-type natriuretic peptide (BNP) concentrations
in relation to 5-year mortality after primary coronary artery bypass
grafting.458 The Journal of Thoracic and Cardiovascular Surgery c Auguanalysis. After statistical adjustment for preoperative LVEF,
POD 1 BNP concentration no longer predicted postoperative
CHF or mortality.14 Another, smaller study reported that
Figure 5. Kaplan–Meier survival curves for all patients to 5 years
after surgery, stratified by preoperative B-type natriuretic peptide
(BNP) greater than 292 pg/mL versus less than or equal to 292 pg/
mL (A) and by preoperative B-type natriuretic peptide greater than
141 pg/mL versus less than or equal to 141 pg/mL (B). Vertical bars
indicate 95% confidence intervals for survival estimates for each
year of postoperative follow-up.st 2008
Fox et al Surgery for Acquired Cardiovascular DiseaseTABLE 5. Effect of adding preoperative B-type natriuretic peptide level to known risk models for mortality after coronary
artery bypass grafting
AIC 22 log Likelihood r2 (%)
Risk score Without With Without With P value* Without With P valuey
Cleveland Clinic 662.556 661.683z 660.556 657.683 .09 5.21 5.78z .016
EuroSCORE
Additive 667.831 666.141z 665.831 662.141 .055 3.95 4.69z .007
Logistic 659.744 659.805 657.744 655.805 .164 5.56 5.94z .048
New York State 679.132 671.661z 677.132 667.661z .002 1.73 3.63z ,.0001
Modified Parsonnet 591.846 587.316z 589.846 583.316z .011 2.06 3.54z .0003
Assessed with proportional hazards models, with the outcome being all-cause mortality during up to 5-year postoperative follow-up. Lower values of Akaike
information criterion and likelihood ratio statistic and higher values of r2 indicate better fit. Because there are numerous methods for comparing global mea-
sures of fit for predictive models, we chose three well-established statistical methods that have penalties for adding variables and for overfitting models. AIC,
Akaike information criterion. *Comparison of nested models under c2 statistic with 1 degree of freedom. yComparison of F statistic of nested models computed
with Nagelkerke r2 (%). zSuperior fit in comparison of models with or without inclusion of log10 preoperative B-type natriuretic peptide concentration.A
CDpreoperative BNP predicted 2-year postoperative survival
after adjustment for preoperative LVEF, Cleveland Clinic
risk score, and postoperative cTnI concentration.13
Wedetermined a preoperativeBNPconcentration cutoff of
greater than 292 pg/mL to be highly specific for development
of postoperative ventricular dysfunction and longer-term (up
to 5-year) mortality. The utility of a BNP cutoff of 292 pg/mL
for patients undergoing primary CABG is further supported
by significantly decreased survival demonstrated in Kaplan–
Meier survival curves stratified by the preoperative BNP
292 pg/mL cutoff. The BNP concentration cutoff in the
literature for diagnosing ambulatory CHF is approximately
100 to 200 pg/mL,3,4 with a 35% increase in relative risk of
death for each 100-pg/mL increment in BNP concentration.5
The higher preoperative BNP cutoff of 292 pg/mL, relative to
the cutoff for diagnosingCHF in ambulatory patients, is likely
related to greater incidences of both preoperative myocardial
ischemia and heart failure in patients undergoing CABG. The
292 pg/mL preoperative BNP cutoff is similar to but some-
what lower than the preoperative BNP cutoff of greater than
385 pg/mL found by Hutfless and associates15 to predict
1-year mortality in 98 male patients undergoing CABG,
some of whom underwent concurrent valve surgery.
We used five risk scoring systems initially developed to
predict in-hospital or 30-day postoperative cardiac surgical
mortality. These five risk models have also been shown to
best predict 1-year mortality in CABG surgical popula-
tions.26 Because our study was underpowered to examine
1-year mortality, we assessed these models’ abilities to
predict up to 5-year all-cause mortality with the addition of
preoperative BNP concentration. Four of these five mortality
risk stratification models showed significant improvements in
at least two of three mortality risk prediction measures when
preoperative BNP concentration was added. The improve-
ment in the logistic EuroSCORE model,24 however, was
seen with only one assessment of model performance.
Overall, these findings support our observation from CoxThe Journal of Thoproportional hazard modeling that preoperative BNP concen-
tration is an important predictor of postoperative mortality.
One reason that mortality prediction did not improve substan-
tially with the addition of preoperative BNP concentration to
the EuroSCORE logistic regression model24 may be that this
model was better than the other four models at predicting
5-year postoperative mortality in our primary CABG popula-
tion. Alternatively, the EuroSCORE logistic regression
model may include or more heavily weight covariates that
have some collinearity with preoperative BNP concentration,
thus reducing the value of adding preoperative BNP con-
centration to this model. The EuroSCORE logistic model’s
inclusion of such covariates as reoperative CABG or other
previous or concurrent cardiac or thoracic aortic surgeries,
emergency surgery, endocarditis, and critical preoperative
state suggests that further investigation may be warranted
to assess the value of preoperative BNP for predictingmortal-
ity in cardiac surgical populations that are at higher risk than
our primary CABG population.
We also observed that plasma BNP concentration
declined after POD 3 in patients who did not have postoper-
ative ventricular dysfunction but remained elevated at least
through POD 5 in patients who did have ventricular dysfunc-
tion. Postoperative BNP concentrations have been shown to
predict long-term morbidity and mortality in cardiac14 and
vascular30 surgical populations. In ambulatory patients with
CHF, aggressive administration of b-blockers and angioten-
sin-converting enzyme inhibitors to reduce plasma BNP con-
centrations below 100 pg/mL has been shown to decrease
CHF-related hospitalizations and mortality.31 Thus there
may be a role for peak postoperative BNP in discriminating
surgical patients who might benefit from aggressive post-
operative therapeutic interventions. Further research is war-
ranted to determine whether BNP concentrations after
cardiac surgery are useful for assessing cardiac function,
targeting postoperative medical therapies, and predicting
long-term morbidity and mortality.racic and Cardiovascular Surgery c Volume 136, Number 2 459
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Several potential limitations of our study deserve consider-
ation. First, this study included only patients undergoing non-
emergency primary CABG alone with CPB. Consequently,
caution should be exercised in extrapolating these findings
to other cardiac surgical populations, including patients
with cardiac valve disease. Second, although we adjusted
for institution in our multivariable analyses, we cannot en-
tirely rule out nonspecific biases introduced by institutional
variations in intraoperative and postoperative management.
Furthermore, we cannot rule out potential bias from individ-
ual practice variations introduced by including multiple sur-
geons in this study. Third, there is no standardized outcome
definition for ventricular dysfunction after cardiac surgery
to guide our study’s ventricular dysfunction outcome defini-
tion. Many patients undergoing primary CABG at both study
institutions do not have perioperative monitoring with trans-
esophageal echocardiography or pulmonary arterial catheter-
ization. We therefore elected to define ventricular
dysfunction after CABG as either a need for two or more ino-
tropes or new IABP or VAD support to ensure that we were
not including patients with normal ventricular function. It is
not standard organizational or surgeon-based practice at ei-
ther institution to separate the patient from CPB with prophy-
lactic inotropic support. Furthermore, we believe that the
significant associations we observed between our ventricular
dysfunction outcome and both extended postoperative hospi-
tal stay and 5-year mortality reinforce the importance of our
in-hospital postoperative ventricular dysfunction outcome.
Fourth, there are multiple available plasma BNP assays,
and the numeric cut points we found should be considered
specific to the analysis platform used in this study.
In light of the high specificity but lower sensitivity of
preoperative BNP concentration cutoffs both in our study
and in that of Hutfless and associates,15 we believe that pre-
operative BNP should be used in conjunction with other clin-
ical predictors delineated in the multivariable models that we
established for postoperative ventricular dysfunction, hospi-
tal stay, and mortality. Importantly, our results should not be
interpreted as meaning that elevated BNP is predictive of
poorer perioperative outcome in the absence of preoperative
cardiovascular compromise. Rather, preoperative BNP may
help discriminate patients who have marginal cardiovascular
reserve despite ambiguous clinical symptoms. Although our
results suggest that patients undergoing primary CABG who
have elevated preoperative BNP concentrations might benefit
from a delay in surgery to allow better preoperative medical
optimization and perioperative planning, this topic needs to
be investigated in future studies.
Conclusions
Our findings support the use of preoperative BNP concentra-
tions along with other clinical predictors to identify patients460 The Journal of Thoracic and Cardiovascular Surgery c Auat risk for in-hospital ventricular dysfunction, longer hospital
stay, and longer-term (up to 5-year) all-cause mortality after
primary CABG with CPB. Additional studies are needed to
assess assay-specific perioperative BNP cutoffs for risk pre-
diction in both patients undergoing primary CABG and other
cardiac surgical groups and to evaluate the efficacy of inter-
ventions such as delaying surgery for medical optimization
on the basis of elevated preoperative BNP concentrations.
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